{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:31:51Z","timestamp":1789835511297,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08304"],"award-info":[{"award-number":["21K08304"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08388"],"award-info":[{"award-number":["22K08388"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11477"],"award-info":[{"award-number":["24K11477"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020377","name":"Maruho Takagi Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006567","name":"Suhara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10147-024-02615-y","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T05:02:10Z","timestamp":1725858130000},"page":"1984-1998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-0095","authenticated-orcid":false,"given":"Tokimasa","family":"Hida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-445X","authenticated-orcid":false,"given":"Junji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8507-1726","authenticated-orcid":false,"given":"Masashi","family":"Idogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-9543","authenticated-orcid":false,"given":"Takashi","family":"Tokino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-3397","authenticated-orcid":false,"given":"Hisashi","family":"Uhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"issue":"7","key":"2615_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681\u20131696. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044","journal-title":"Cell"},{"key":"2615_CR2","unstructured":"Elder D, Barnhill R, Bastian B (2018) Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. In: Elder D, Massi D, Scolyer R, Willemze R (eds) WHO Classification of Skin Tumours, Vol. 11, 4th edn. IARC, Lyon, pp 66\u201371"},{"issue":"7653","key":"2615_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545(7653):175\u2013180. https:\/\/doi.org\/10.1038\/nature22071","journal-title":"Nature"},{"key":"2615_CR4","unstructured":"National Comprehensive Cancer Network (2024) Melanoma; Cutaneous, Version 2, NCCN clinical practice guidelines in oncology. Available from: https:\/\/www.nccn.org\/home. Accessed May 2024"},{"issue":"3","key":"2615_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/1346-8138.17093","volume":"51","author":"S Fukushima","year":"2024","unstructured":"Fukushima S, Miyashita A, Kimura T et al (2024) Deciphering the role of adjuvant therapy in melanoma and its actual benefits. J Dermatol 51(3):335\u2013342. https:\/\/doi.org\/10.1111\/1346-8138.17093","journal-title":"J Dermatol"},{"issue":"2","key":"2615_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/1346-8138.15151","volume":"47","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Asai J, Igaki H et al (2020) Japanese dermatological association guidelines: outlines of guidelines for cutaneous melanoma 2019. J Dermatol 47(2):89\u2013103. https:\/\/doi.org\/10.1111\/1346-8138.15151","journal-title":"J Dermatol"},{"issue":"3","key":"2615_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjd.21241","volume":"187","author":"X Bai","year":"2022","unstructured":"Bai X, Shoushtari AN, Betof Warner A et al (2022) Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. Br J Dermatol 187(3):401\u2013410. https:\/\/doi.org\/10.1111\/bjd.21241","journal-title":"Br J Dermatol"},{"issue":"14","key":"2615_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"2615_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2022.08.030","volume":"176","author":"Y Nakamura","year":"2022","unstructured":"Nakamura Y, Namikawa K, Kiniwa Y et al (2022) Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: a retrospective, multicenter study of 254 Japanese patients. Eur J Cancer 176:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.030","journal-title":"Eur J Cancer"},{"issue":"4","key":"2615_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/1346-8138.16669","volume":"50","author":"A Takahashi","year":"2023","unstructured":"Takahashi A, Namikawa K, Ogata D et al (2023) Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. J Dermatol 50(4):525\u2013535. https:\/\/doi.org\/10.1111\/1346-8138.16669","journal-title":"J Dermatol"},{"issue":"1","key":"2615_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","volume":"80","author":"K Sakaizawa","year":"2015","unstructured":"Sakaizawa K, Ashida A, Uchiyama A et al (2015) Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci 80(1):33\u201337. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.07.012","journal-title":"J Dermatol Sci"},{"issue":"1","key":"2615_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdermsci.2023.03.008","volume":"110","author":"T Inozume","year":"2023","unstructured":"Inozume T, Namikawa K, Kato H et al (2023) Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: a retrospective real-world, multicenter study. J Dermatol Sci 110(1):19\u201326. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.03.008","journal-title":"J Dermatol Sci"},{"issue":"12","key":"2615_CR13","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA et al (2019) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(12):1884\u20131901. https:\/\/doi.org\/10.1093\/annonc\/mdz411","journal-title":"Ann Oncol"},{"issue":"11","key":"2615_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T, Kato M, Kohsaka S et al (2022) C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov 12(11):2509\u20132515. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0417","journal-title":"Cancer Discov"},{"issue":"11","key":"2615_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31(11):1023\u20131031. https:\/\/doi.org\/10.1038\/nbt.2696","journal-title":"Nat Biotechnol"},{"key":"2615_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.2004088","journal-title":"Sci Signal"},{"issue":"1","key":"2615_CR17","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS et al (2019) Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun 10(1):3163. https:\/\/doi.org\/10.1038\/s41467-019-11107-x","journal-title":"Nat Commun"},{"issue":"1","key":"2615_CR18","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","volume":"11","author":"F Newell","year":"2020","unstructured":"Newell F, Wilmott JS, Johansson PA et al (2020) Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun 11(1):5259. https:\/\/doi.org\/10.1038\/s41467-020-18988-3","journal-title":"Nat Commun"},{"issue":"6","key":"2615_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1541-7786.MCR-20-0839","volume":"19","author":"N Broit","year":"2021","unstructured":"Broit N, Johansson PA, Rodgers CB et al (2021) Meta-analysis and systematic review of the genomics of mucosal melanoma. Mol Cancer Res 19(6):991\u20131004. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0839","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2615_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/pcmr.13034","volume":"35","author":"N Broit","year":"2022","unstructured":"Broit N, Johansson PA, Rodgers CB et al (2022) Systematic review and meta-analysis of genomic alterations in acral melanoma. Pigment Cell Melanoma Res 35(3):369\u2013386. https:\/\/doi.org\/10.1111\/pcmr.13034","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"2615_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","volume":"14","author":"SP Suehnholz","year":"2024","unstructured":"Suehnholz SP, Nissan MH, Zhang H et al (2024) Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov 14(1):49\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0467","journal-title":"Cancer Discov"},{"issue":"4","key":"2615_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/pcmr.12865","volume":"33","author":"Z Zou","year":"2020","unstructured":"Zou Z, Ou Q, Ren Y et al (2020) Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling. Pigment Cell Melanoma Res 33(4):601\u2013611. https:\/\/doi.org\/10.1111\/pcmr.12865","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"2615_CR23","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1038\/s41598-022-13391-y","volume":"12","author":"F Huang","year":"2022","unstructured":"Huang F, Li J, Wen X et al (2022) Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Sci Rep 12(1):9559. https:\/\/doi.org\/10.1038\/s41598-022-13391-y","journal-title":"Sci Rep"},{"issue":"1","key":"2615_CR24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41467-022-28566-4","volume":"13","author":"F Farshidfar","year":"2022","unstructured":"Farshidfar F, Rhrissorrakrai K, Levovitz C et al (2022) Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun 13(1):898. https:\/\/doi.org\/10.1038\/s41467-022-28566-4","journal-title":"Nat Commun"},{"issue":"10","key":"2615_CR25","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/jnci\/djz005","volume":"111","author":"I Yeh","year":"2019","unstructured":"Yeh I, Jorgenson E, Shen L et al (2019) Targeted genomic profiling of acral melanoma. J Natl Cancer Inst 111(10):1068\u20131077. https:\/\/doi.org\/10.1093\/jnci\/djz005","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2615_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jid.2017.11.017","volume":"138","author":"KR Moon","year":"2018","unstructured":"Moon KR, Choi YD, Kim JM et al (2018) Genetic alterations in primary acral melanoma and acral melanocytic nevus in Korea: common mutated genes show distinct cytomorphological features. J Invest Dermatol 138(4):933\u2013945. https:\/\/doi.org\/10.1016\/j.jid.2017.11.017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2615_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/ijms23010147","volume":"23","author":"A Indini","year":"2021","unstructured":"Indini A, Roila F, Grossi F et al (2021) Molecular profiling and novel therapeutic strategies for mucosal melanoma: a comprehensive review. Int J Mol Sci 23(1):147. https:\/\/doi.org\/10.3390\/ijms23010147","journal-title":"Int J Mol Sci"},{"key":"2615_CR28","unstructured":"Coupland S, Folberg R, Kivela T et al (2018) Ocular melanocytic tumours, Uveal melanoma. In: Elder D, Massi D, Scolyer R, Willemze R (eds) WHO Classification of Skin Tumours, Vol. 11, 4th edn. IARC, Lyon, pp137\u2013138"},{"issue":"1","key":"2615_CR29","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/s41467-020-15606-0","volume":"11","author":"J Karlsson","year":"2020","unstructured":"Karlsson J, Nilsson LM, Mitra S et al (2020) Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun 11(1):1894. https:\/\/doi.org\/10.1038\/s41467-020-15606-0","journal-title":"Nat Commun"},{"key":"2615_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","volume":"157","author":"T Steeb","year":"2021","unstructured":"Steeb T, Wessely A, Petzold A et al (2021) c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. Eur J Cancer 157:348\u2013357. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.015","journal-title":"Eur J Cancer"},{"issue":"5","key":"2615_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/pcmr.12388","volume":"28","author":"AM Menzies","year":"2015","unstructured":"Menzies AM, Yeh I, Botton T et al (2015) Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res 28(5):607\u2013610. https:\/\/doi.org\/10.1111\/pcmr.12388","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"2615_CR32","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1172\/JCI123089","volume":"129","author":"CR McEvoy","year":"2019","unstructured":"McEvoy CR, Xu H, Smith K et al (2019) Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4\u2013RAF1 fusion. J Clin Invest 129(5):1940\u20131945. https:\/\/doi.org\/10.1172\/JCI123089","journal-title":"J Clin Invest"},{"issue":"5","key":"2615_CR33","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.gendis.2022.11.014","volume":"10","author":"R Jiang","year":"2023","unstructured":"Jiang R, Liang X, Tao Y et al (2023) Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma. Genes Dis 10(5):1755\u20131758. https:\/\/doi.org\/10.1016\/j.gendis.2022.11.014","journal-title":"Genes Dis"},{"issue":"23","key":"2615_CR34","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1158\/1078-0432.CCR-18-1397","volume":"24","author":"LS Gottesdiener","year":"2018","unstructured":"Gottesdiener LS, O\u2019Connor S, Busam KJ et al (2018) Rates of ERBB2 alterations across melanoma subtypes and a complete response to trastuzumab emtansine in an ERBB2-amplified acral melanoma. Clin Cancer Res 24(23):5815\u20135819. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1397","journal-title":"Clin Cancer Res"},{"key":"2615_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106807","volume":"152","author":"N Ichimura","year":"2024","unstructured":"Ichimura N, Urata Y, Kobayashi T et al (2024) Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort. Oral Oncol 152:106807. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106807","journal-title":"Oral Oncol"},{"key":"2615_CR36","doi-asserted-by":"publisher","first-page":"17967","DOI":"10.1002\/cam4.6438","volume":"12","author":"K Namikawa","year":"2023","unstructured":"Namikawa K, Ito T, Yoshikawa S et al (2023) Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study). Cancer Med 12:17967\u201317980. https:\/\/doi.org\/10.1002\/cam4.6438","journal-title":"Cancer Med"},{"key":"2615_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100325","volume":"6","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Namikawa K, Yoshikawa S et al (2021) Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open 6:100325. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100325","journal-title":"ESMO Open"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02615-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02615-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02615-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:45:43Z","timestamp":1732639543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02615-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2615"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02615-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tokimasa Hida received research funds from Maruho Takagi Dermatology Foundation and Suhara Memorial Foundation. The other authors declare that there are no conflicts of interest regarding this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Review Board of Sapporo Medical University Hospital (#282-224) and the C-CAT Information Utilization Review Board (CDU2023-033N) approved this study. Informed consent was obtained from all patients at each institution, allowing their data to be deposited in the C-CAT database for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participation and publication"}}]}}